Investigators assessed disparities in patient access to therapies approved for the treatment of gastrointestinal malignancies in the United States, the United Kingdom, Europe, and Ireland, as well as benefit relative to cost.
This exploratory subgroup analysis of the TAGS study assessed the efficacy, safety, and quality of life (QOL) results observed in patients who received trifluridine/tipiracil or placebo in the third- or later-line settings.
Bernstam et al presented findings from an expansion cohort of a phase 1 trial testing the bispecific HER2-targeted antibody zanidatamab in patients with HER2-overexpressing biliary tract cancer.
Outcomes of lenvatinib-receiving patients who progressed to Child-Pugh B liver function within the first 8 weeks of treatment were compared with those of patients who maintained Child-Pugh A classification during the same time period.
The phase 1b/2 PLANET study tested the combination of lanreotide and pembrolizumab in advanced well- or moderately differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Investigators present findings from a phase 1a study evaluating the safety and efficacy of MIV-818 in patients with hepatocellular carcinoma (HCC), hepatic cholangiocarcinoma (CCA), or liver metastases from solid tumors.
Kasi et al compared a novel, artificial intelligence (AI)-based cancer clinical trial search tool with ClinicalTrials.gov to determine which afforded a better user experience.
Investigators of the phase 1b/2 PANTHERA trial presented updated clinical and molecular profiling data from 43 patients who received frontline pembrolizumab, trastuzumab, and chemotherapy.
This post hoc analysis of KEYNOTE-240 was performed to determine whether objective response at landmark is prognostic of longer survival after landmark time.
Investigators of the SUMMIT basket trial evaluated the efficacy of neratinib both as a monotherapy and in combination with other agents in patients with fibrolamellar carcinoma (FLC).
LEAP-005 investigators tested the safety and efficacy of combination lenvatinib and pembrolizumab in 32 patients with previously treated advanced non–microsatellite instability-high (MSI-H)/mismatch repair proficient (pMMR) colorectal cancer (CRC).
COBRA investigators will evaluate circulating tumor DNA (ctDNA) as a biomarker for adjuvant chemotherapy benefit in 1408 patients with resected, stable stage IIA colon cancer.
Investigators reviewed data from 202,237 patients from the Surveillance, Epidemiology, and End Results (SEER) registry who had been diagnosed CRC with 2010 and 2015.
